Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial

Anthony D. Ormerod, Kim S. Thomas*, Fiona E. Craig, Eleanor Mitchell, Nicola Greenlaw, John Norrie, James M. Mason, Shernaz Walton, Graham A. Johnston, Hywel C. Williams, Uk Dermatology Clinical Trials Net

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

115 Citations (Scopus)
3 Downloads (Pure)


Objective: To determine whether ciclosporin is superior to prednisolone for the treatment of pyoderma gangrenosum, a painful, ulcerating skin disease with a poor evidence base for management.

Design: Multicentre, parallel group, observer blind, randomised controlled trial.

Setting: 39 UK hospitals, recruiting from June 2009 to November 2012.

Participants : 121 patients (73 women, mean age 54 years) with clinician diagnosed pyoderma gangrenosum. Clinical diagnosis was revised in nine participants after randomisation, leaving 112 participants in the analysis set (59 ciclosporin; 53 prednisolone).

Intervention: Oral prednisolone 0.75 mg/kg/day compared with ciclosporin 4 mg/kg/day, to a maximum dose of 75 and 400 mg/day, respectively.

Main outcome measures: The primary outcome was speed of healing over six weeks, captured using digital images and assessed by blinded investigators. Secondary outcomes were time to healing, global treatment response, resolution of inflammation, self reported pain, quality of life, number of treatment failures, adverse reactions, and time to recurrence. Outcomes were assessed at baseline and six weeks and when the ulcer had healed (to a maximum of six months).

Original languageEnglish
Article number2958
Number of pages8
Publication statusPublished - 12 Jun 2015


  • inflammatory-bowel-disease
  • United-Kingdom
  • cyclosporine
  • therapy
  • multicenter
  • management
  • diagnosis
  • update
  • index

Cite this